



MedAdvisor Limited  
ACN 145 327 617  
Level 2, 971 Burke Road  
Camberwell Vic 3124  
[mymedadvisor.com/investors](http://mymedadvisor.com/investors)

**ASX RELEASE (ASX: MDR)**

## **MedAdvisor strengthens Board for next stage of growth**

### **Key highlights:**

- **Kate Hill appointed as non-executive director and Chair of the Audit and Risk Committee**
- **Brett Magun appointed as US-based non-executive director nominated by Cotiviti Inc.**
- **Non-executive director Sandra Hook appointed Chair of the People, Remuneration and Nominations Committee**

**Melbourne, Australia, 26 May, 2023** – Medtech company, MedAdvisor Limited (the **Company**) (ASX: MDR) today announced the appointment of Kate Hill and Brett Magun as non-executive directors, effective 24 May 2023.

Ms Hill is an experienced non-executive director and previously spent over 20 years as an audit partner at Deloitte, serving both ASX listed and privately owned clients. Kate has particular expertise at board level in both technology companies and also the biotech and medical devices sectors.

Mr Magun is the nominated board member of Cotiviti Inc. (**Cotiviti**), replacing RaeAnn Grossman who resigned on 21 April 2023. Cotiviti is a leading healthcare technology business in the United States. Brett will add valuable guidance for the continued expansion of MedAdvisor's business in the United States.

Ms Sandra Hook has been appointed as Chair of the People, Remuneration and Nominations Committee. Current Chair of the People, Remuneration and Nominations Committee, Jim Xenos will step down as Chair and continue to support the business with a focus on the expansion of the capability in the Australian market. Kate Hill will become Chair of the Audit and Risk Committee, previously held by Sandra Hook. These committee changes take effect 1 July 2023.

## **Kate Hill**

Kate is an experienced non-executive director of ASX-listed companies and brings expertise at board level in leading change involving new business models, markets and technologies in the biotech and medical device sectors. In addition, she has experience on other listing exchanges including Nasdaq (US) and AIM (UK).

Kate spent more than 20 years as an audit partner at Deloitte, serving both ASX-listed and private clients. She has deep experience helping companies navigate evolving operating environments – with a focus on sustainable growth leading to profitability along with extensive M&A and capital raising experience; and stakeholder engagement including investor relations, proxy solicitation and media management.

Kate has strong governance skills with deep expertise in all aspects of compliance in regulated markets and Audit and Risk Committee leadership.

She has a Bachelor of Science (Honours) in Mathematics and Statistics from Bristol University.

## **Brett Magun**

Brett Magun is the Senior Vice President, General Counsel and Corporate Secretary of Cotiviti, Inc. where he oversees the company's legal and compliance functions globally. This includes advising the Company and its Board on employment, corporate, contractual, and complex corporate transaction-related risks and solutions.

Brett has spent more than 25 years as an in-house corporate attorney providing counsel for large corporations and start-ups, both domestically and abroad. These include General Counsel to Richard Branson's Virgin Money US entity, and various legal roles for KPMG in the Netherlands and Bear Stearns in New York City.

Brett has a Juris Doctorate from Brooklyn Law School where he was a Richardson Scholar and a Bachelor of Science in Business Administration from Boston University.

**Commenting on the changes, MedAdvisor's Board Chair Linda Jenkinson said:** "As MedAdvisor enters its' next stage of growth, Kate and Brett's appointments not only strengthen our board, but show how we are evolving to meet the growing needs of the business as we scale in the US, expand our digital reach and build our global platform.

"We are delighted Cotiviti has selected Brett as its board representative. He will bring a wealth of experience that will help the execution of our growth strategy.

"On behalf of the Board, I thank Jim for his valuable contributions as Chair of the People, Remuneration and Nominations Committee and look forward to his continued contributions as a board member. Having served as member of this committee since 2016, Sandra is the ideal new Chair of the People, Remuneration and Nominations Committee."

**Commenting on her appointment as a non-executive director of MedAdvisor, Ms. Hill said:** “I am excited to be joining MedAdvisor at this pivotal time in its history and look forward to bringing my extensive experience in risk and audit to help support execution of our business and growth strategy. ”

**Commenting on his appointment as a non-executive director of MedAdvisor, Mr. Magun said:** “MedAdvisor is in an excellent position to scale its business in the United States. I am keen to contribute to the company’s growth ambitions as it uses its multi-channel digital medication management solutions to gain market share, particularly throughout the US pharmacy network.”

- ENDS -

*This announcement has been authorised for release by the Board of MedAdvisor Limited.*

**For more information please contact:**

**Company**

Ancila Desai  
Chief Financial Officer and Company  
Secretary  
[corporate@medadvisor.com.au](mailto:corporate@medadvisor.com.au)  
+613 9095 3036

**Investors**

Ronn Bechler, Automic Markets  
[ronn.bechler@automicgroup.com.au](mailto:ronn.bechler@automicgroup.com.au)  
+61 400 009 774

**Media**

Tristan Everett, Automic Markets  
[tristan.everett@automicgroup.com.au](mailto:tristan.everett@automicgroup.com.au)  
+61 403 789 096

**About MedAdvisor**

*MedAdvisor is a world-class medication management platform that empowers patients to more simply manage their medication and improve adherence. MedAdvisor’s highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 32,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 3.1 million patients through more than 90% of Australian pharmacies. MedAdvisor is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100 and in 2022 and 2023 Adheris Health, a MedAdvisor company, received the Retail Excellence Award (REX) for Technology & Automation from Drug Store News. Visit: <https://www.mymedadvisor.com/>*